Short answer: there is no single answer — and that's the whole problem. CBD's legal status for use in supplements is one of the most divergent regulatory questions in the wellness industry. The same CBD isolate can be a freely sold ingredient nowhere, a scheduled substance in one country, a "novel food" needing authorisation in another, and a prescription-only compound in a third. If you sell across borders, treating CBD as one thing with one status is how brands get caught out.
Here's where five major markets actually stand in 2026.
United States — federally "legal," but not as a supplement
This is the distinction that trips up almost everyone. Under the 2018 Farm Bill, hemp — cannabis containing no more than 0.3% delta-9 THC by dry weight — was removed from the Controlled Substances Act. So hemp-derived CBD is, in that narrow sense, federally lawful.
But that does not make it a legal dietary supplement. The FDA's position is unambiguous: CBD is excluded from the dietary-supplement definition under the drug-preclusion provision of the Food, Drug & Cosmetic Act, because CBD was first approved as a prescription drug (Epidiolex). In the FDA's own words, the answer to "can CBD be sold as a dietary supplement?" is no. The agency continues to pursue companies marketing CBD with drug claims or in ways attractive to children.
On top of that, the ground is shifting hard: a new federal definition of hemp takes effect on 12 November 2026, narrowing what counts as legal hemp — excluding synthesised cannabinoids and capping total intoxicating cannabinoids at a very low threshold per container. Many products legal today will fall back under the Controlled Substances Act as marijuana. (Some bills propose delaying this, so it's worth watching.) And all of this sits on top of a state-by-state patchwork, where individual states impose their own bans, age limits, and licensing.
Bottom line for brands: selling CBD as a "supplement" in the US carries real federal risk today, and the rules tighten further in late 2026.
European Union — a "novel food" with no authorisation yet
In the EU, CBD extracts and isolates used in food and supplements are treated as novel foods under Regulation (EU) 2015/2283. That means they require pre-market authorisation before they can legally be sold — and to date, no CBD novel food application has been authorised. More than 60 applications have been submitted; many have been terminated or rejected for insufficient safety data.
In early 2026, EFSA proposed a provisional safe intake of roughly 2 mg per day for adults — strikingly low, and a signal of how cautious the science assessment has become. Enforcement varies by member state, with some (such as Germany and Austria) taking a strict line. Separately, health claims on CBD products ("stress relief", "sleep", "anti-inflammatory") are restricted under EU nutrition-and-health-claims rules regardless of the novel food question.
Bottom line for brands: ingestible CBD is not freely sellable in the EU. Without authorisation, it's an unauthorised novel food.
United Kingdom — a separate, more pragmatic path
Post-Brexit, Great Britain runs its own novel food regime through the Food Standards Agency, mirroring the EU framework but with a more pragmatic enforcement stance. The FSA has allowed products that were on the market before its cut-off and are linked to a credible, progressing application to remain on sale in England and Wales while their applications are assessed — a "proportionate" approach the EU does not take. The FSA continues to review applications and maintains cautious guidance on maximum daily intake and restrictive labelling.
Bottom line for brands: the UK is more workable than the EU, but only if your product is properly in the FSA's process — not simply on a shelf.
Australia — scheduled, not a free-for-sale supplement
Australia treats CBD through the Poisons Standard. Low-dose CBD that meets strict criteria (high CBD purity, very low THC, within set dose and route limits) sits in Schedule 3 — pharmacist-only — while higher-dose CBD is Schedule 4 (prescription only), THC-dominant products are Schedule 8 (controlled), and other cannabis is Schedule 9 (prohibited). In other words, CBD is a scheduled substance, not an off-the-shelf supplement ingredient, and the exact tier depends on composition.
Bottom line for brands: you can't simply list a CBD "supplement" in Australia — its scheduling governs everything.
Canada — legal, but only under the Cannabis Act
In Canada, CBD is regulated under the Cannabis Act, and all phytocannabinoids sit on the Prescription Drug List. Critically, cannabis is expressly excluded from the Natural Health Products Regulations — so there is currently no legal pathway to sell a non-prescription CBD supplement making health claims. CBD products are sold only through licensed, age-restricted cannabis channels. Health Canada has been exploring a future pathway to allow CBD health products without practitioner oversight, but it isn't in force.
Bottom line for brands: CBD can't be sold as a vitamin-aisle supplement in Canada today.
The real lesson
CBD is the clearest example of why "is this ingredient legal?" is the wrong question. The right question is "what is this ingredient's status in each market I sell into — and has it changed recently?" For CBD, the answers in 2026 range from "scheduled" to "novel-food-unauthorised" to "not a lawful supplement at all", and at least one of those markets changes again in November.
This is exactly the kind of cross-market divergence Regulave is built to surface. When you check a label or formulation, we flag a scheduled or restricted ingredient against each market separately and link you to the primary regulation behind it — so you see CBD's four different answers in one place, instead of discovering them one fine at a time.
Last reviewed: June 2026. Regulatory status changes frequently — this article is general information, not legal advice, and you should verify the current position with the relevant regulator or a qualified professional before making product decisions. Check an ingredient across 22 markets with Regulave →